Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Efficacy of Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Resistant to or Intolerant of Imatinib: Updated Results of the CA180013 ‘START-C’ Phase II Study.

Michele Baccarani, H.M. Kantarjian, J.F. Apperley, J.H. Lipton, B. Druker, A. Countouriotis, R. Ezzeddine, A. Hochhaus

Blood (2006) 108 (11): 164.

https://doi.org/10.1182/blood.V108.11.164.164

Published: 2006

Journal Articles

Dasatinib (SPRYCEL®) Efficacy and Safety in Patients (pts) with Chronic Myelogenous Leukemia in Lymphoid (CML-LB) or Myeloid Blast (CML-MB) Phase Who Are Imatinib-Resistant (Im-r) or -Intolerant (Im-i).

Giovanni Martinelli, A. Hochhaus, S. Coutre, J.F. Apperley, N. Shah, A. Gollerkeri, P. Agarwal, O.G. Ottmann

Blood (2006) 108 (11): 745.

https://doi.org/10.1182/blood.V108.11.745.745

Published: 2006

Journal Articles

Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START-A’ Phase II Study.

Jorge Cortes, D.W. Kim, F. Guilhot, G. Rosti, R.T. Silver, A. Gollerkeri, P. Agarwal, S. Branford, J.F. Apperley

Blood (2006) 108 (11): 2160.

https://doi.org/10.1182/blood.V108.11.2160.2160

Published: 2006

Journal Articles

A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 ‘START-A’ Study.

Francois Guilhot, J.F. Apperley, N. Shah, D.W. Kim, A. Grigg, S. Cheng, M. Iyer, J. Cortes

Blood (2005) 106 (11): 39.

https://doi.org/10.1182/blood.V106.11.39.39

Published: 2005

Journal Articles

HLA-B8 and HLA-A3 Coexpressed With HLA-B8 Are Associated With a Reduced Risk of the Development of Chronic Myeloid Leukemia

E.F.M. Posthuma, J.H.F. Falkenburg, J.F. Apperley, A. Gratwohl, E. Roosnek, B. Hertenstein, R.F. Schipper, G.M.T. Schreuder, J. D’Amaro, M. Oudshoorn, J.H. v Biezen, J. Hermans, R. Willemze, D. Niederwieser

Blood (1999) 93 (11): 3863–3865.

https://doi.org/10.1182/blood.V93.11.3863

Published: 1999

Journal Articles

Persistence of Antibody to Human Parvovirus B19 After Allogeneic Bone Marrow Transplantation: Role of Prior Recipient Immunity

H.A. Ang, J.F. Apperley, K.N. Ward

Blood (1997) 89 (12): 4646–4651.

https://doi.org/10.1182/blood.V89.12.4646

Published: 1997

NARROW

Efficacy of Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Resistant to or Intolerant of Imatinib: Updated Results of the CA180013 ‘START-C’ Phase II Study.

Dasatinib (SPRYCEL®) Efficacy and Safety in Patients (pts) with Chronic Myelogenous Leukemia in Lymphoid (CML-LB) or Myeloid Blast (CML-MB) Phase Who Are Imatinib-Resistant (Im-r) or -Intolerant (Im-i).

Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START-A’ Phase II Study.

A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 ‘START-A’ Study.

HLA-B8 and HLA-A3 Coexpressed With HLA-B8 Are Associated With a Reduced Risk of the Development of Chronic Myeloid Leukemia

Persistence of Antibody to Human Parvovirus B19 After Allogeneic Bone Marrow Transplantation: Role of Prior Recipient Immunity

Email alerts

ASH Publications

American Society of Hematology

Efficacy of Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Resistant to or Intolerant of Imatinib: Updated Results of the CA180013 ‘START-C’ Phase II Study.

Dasatinib (SPRYCEL®) Efficacy and Safety in Patients (pts) with Chronic Myelogenous Leukemia in Lymphoid (CML-LB) or Myeloid Blast (CML-MB) Phase Who Are Imatinib-Resistant (Im-r) or -Intolerant (Im-i).

Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START-A’ Phase II Study.

A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 ‘START-A’ Study.

HLA-B8 and HLA-A3 Coexpressed With HLA-B8 Are Associated With a Reduced Risk of the Development of Chronic Myeloid Leukemia

Persistence of Antibody to Human Parvovirus B19 After Allogeneic Bone Marrow Transplantation: Role of Prior Recipient Immunity

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only